(Reuters)—Abbvie Inc. says its experimental drug met the main goal of halting progression of moderate to severe rheumatoid arthritis (RA) in a late-stage trial. The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate. Upadacitinib, which belongs to a class of drugs known as JAK inhibitors,…
Research Shows High Adherence to Performance Measures for RA Cohort
New research examines the adherence rates for system-level performance measures in Canada. Using data from the Canadian Early Arthritis Cohort that spanned eight years, researchers determined the percentage of RA patients seen in yearly follow-up with the number of gaps between visits, the percentage of RA patients treated with a disease-modifying anti-rheumatic drug and number days from diagnosis to the initiation of treatment. The results: High adherence to system-level performance measures was found in this early RA cohort, with small declines in performance with the increasing length overtime…
Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
NEW YORK (Reuters Health)—Children of women with rheumatoid arthritis (RA) who are exposed to tumor necrosis factor-alpha inhibitors (TNFis) in the womb are not at markedly increased risk of serious infections, new findings suggest. “It’s reassuring for mothers who need to take these medications during pregnancy,” Evelyne Vinet, MD, of McGill University Health Center in…
Gut Microbiota Directly Affects Inflammatory Arthritis
Gut microbiota may provide insight into important environmental triggers for autoimmune diseases. New research in mice indicates that intestinal dysbiosis triggers a mucosal immune response that stimulates T and B cells, which are critical to the development of inflammatory arthritis…
RA Patients May Not Receive Needed Osteoporosis Screening & Treatment
New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…
Obesity Linked with Disability in RA
(Reuters Health)—Patients with rheumatoid arthritis (RA) may be more likely to become disabled if they’re obese, a U.S. study suggests. Researchers examined data on more than 25,000 patients with RA. Most were overweight or obese when they joined the study. Those who were severely obese were more likely to report some disability at baseline. Over…
FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib
(Reuters)—An experimental rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp. poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff says, the latest setback to a treatment regulators declined to approve last year. New data provided by the companies in a resubmission of their marketing…
Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
Initial results from an ongoing trial show that upadacitinib outperforms adalimumab in achieving ACR20 in patients with rheumatoid arthritis…
Periodontitis May Provide Insight into RA
Researchers explored the role of carbamylated protein (CarP) and neutrophil extracellular traps (NETs) in periodontitis and rheumatoid arthritis (RA). The results showed significantly higher levels of CarP and NETs in patients with both RA and periodontitis than in healthy controls. The data suggest that RA and periodontitis may share an underlying pathogenic mechanism…
Synovial Analysis Identifies Distinct Rheumatoid Arthritis Subtypes
NEW YORK (Reuters Health)—Synovial gene expression and histology can be used to divide rheumatoid arthritis (RA) into high, low, and mixed inflammatory subtypes, according to results from the Accelerating Medicine Partnership: RA/SLE Network. “The actionable implication of these findings is that it may be worth considering synovial biopsies in patients who are not responding to…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 30
- Next Page »